Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04577781
Other study ID # GLPG3970-CL-209
Secondary ID 2020-000658-83
Status Completed
Phase Phase 2
First received
Last updated
Start date October 12, 2020
Est. completion date April 7, 2021

Study information

Verified date March 2022
Source Galapagos NV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date April 7, 2021
Est. primary completion date March 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Key Inclusion Criteria: 1. A body mass index (BMI) between 18-32 kg/m^2, inclusive. 2. Diagnosis of RA =6 months prior to screening AND meeting the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria of RA AND ACR functional class I-III. 3. Have =6 swollen joints (from a swollen joint count evaluated in 66 joints [SJC66]) AND =8 tender joints (from a tender joint count evaluated in 68 joints [TJC68]) at screening and at the baseline visit (Visit 1) prior to the first investigational product (IP) dosing. 4. DAS28 (CRP) >3.2 (moderate disease) at screening. 5. Screening serum high sensitivity C-reactive protein (hsCRP) > upper limit of normal (ULN, central laboratory reference: = 5.0 mg/L). 6. Inadequate response to MTX, i.e. treatment-experienced participants who demonstrated inadequate clinical response during treatment with MTX. 7. Have received MTX for =6 months and on stable dose (10 to 20 mg/week) of MTX for at least 4 weeks prior to screening and willing to continue on their current stable dose and dosing regimen for the duration of the study. 8. If taking systemic steroids, prednisone equivalent at a dose of =10 mg/day and stable for at least 4 weeks prior to the first IP dosing. Key Exclusion Criteria: 1. Current therapy with any conventional disease-modifying antirheumatic drug (DMARD) other than MTX, including 1. oral or injectable gold, sulfasalazine, antimalarials, azathioprine, or D-penicillamine within 4 weeks prior to screening, 2. cyclosporine within 8 weeks prior to screening, and 3. leflunomide within 3 months prior to screening or a minimum 4 weeks prior to screening if after 11 days of standard cholestyramine therapy. 2. Current or previous treatment with a biologic DMARD (bDMARD). Except for participants who received bDMARDs only in a single clinical study setting: 1. For whom the last dose of bDMARD =6 months prior to screening (12 months for rituximab or other lymphocyte depleting agents), AND; 2. For whom the bDMARD was effective, without being discontinued due to lack of efficacy. 3. Participants who received an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening. 4. Participants who received a prior surgical intervention within 12 weeks prior to screening or likely requirement for surgery during the study. 5. Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis as defined by one of the following assessments: 1. Positive QuantiFERON-TB Gold test result at screening, OR 2. Chest radiograph (posterior anterior view) taken within 12 weeks prior to screening, read by a qualified radiologist or pulmonologist, with evidence of current active TB or old inactive TB. 6. Participant has any active systemic infection within the last 2 weeks prior to first IP dosing, or poorly controlled chronic cardiac, pulmonary or renal disease. 7. Participant has a known or suspected history of or a current immunosuppressive condition, or a history of invasive opportunistic infections (e.g. human immunodeficiency virus [HIV] infection, histoplasmosis, listeriosis, coccidiodmycosis, pneumocystosis, aspergillosis). 8. Participant has a chronic hepatitis B virus (HBV) infection, as defined by persistent HBV surface antigen (HBsAg) positivity. Participant has hepatitis C virus (HCV) infection, as defined by positive HCV antibody at screening and detectable HCV viremia. Participants with positive HCV antibody must undergo reflex HCV ribonucleic acid (RNA) testing, and participants with HCV RNA positivity will be excluded. Participants with positive HCV antibody and negative HCV RNA are eligible. 9. Participant testing positive at screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as detected by real time polymerase chain reaction (RT-PCR), participants presenting any signs or symptoms as detected at baseline following careful physical examination (e.g. cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, others) or reporting any signs and symptoms for the 2 preceding weeks, or participants who have been exposed to individuals with confirmed or suspected diagnosis of SARS-CoV-2 within 2 weeks prior to baseline. In addition, any other locally applicable standard diagnostic criteria may also apply to rule out SARS-CoV-2 infection. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GLPG3970
GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
Placebo
Placebo powder and solvent for oral solution to be reconstituted prior to use.

Locations

Country Name City State
Bulgaria Medical Center Teodora Ruse
Bulgaria UMHAT Sv. Ivan Rilski EAD Sofia
Georgia Aversi Clinic Ltd Tbilisi
Georgia Consilium Medulla-multiprofile clinic Ltd Tbilisi
Poland Centrum Badan Klinicznych S.C. Poznan
Poland Centrum Medyczne Grunwald Poznan
Ukraine GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine Kharkiv
Ukraine SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU Vinnytsia
Ukraine Medical Center Clinic of Modern Rheumatology Zaporizhzhya

Sponsors (1)

Lead Sponsor Collaborator
Galapagos NV

Countries where clinical trial is conducted

Bulgaria,  Georgia,  Poland,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in DAS-28 (CRP) at Week 6 The DAS28 (CRP) is a derived measurement with differential weighting given to each component such as TJC28, SJC28, patient's global assessment of disease activity, and serum CRP level.
TJC28 ranges from 0-28
SJC28 ranges from 0-28
High sensitivity C-reactive protein (hsCRP) (in mg/L)
Patient's disease activity VAS (in mm) (ranges from 0 = best to 100 = worst)
The DAS28 (CRP) score was calculated using the below formula:
DAS28 (CRP) = 0.56 x square root of TJC28 + 0.28 x square root of SJC28 + 0.36 x Ln[1+CRP(in mg/L)] + 0.014 x patient's disease activity VAS (in mm) + 0.96. A lower score is considered as better disease activity.
Baseline and Week 6
Secondary Number of Participants With Treatment Emergent Adverse Events Treatment-Emergent Adverse Events (TEAE) were defined as
Any adverse event (AE) with an onset date on or after the IP start date and no later than 14 days after last dose of IP, or worsening of any AE on or after the IP start date.
Improvement or no change of any ongoing AEs on or after the IP start date are not considered treatment-emergent. If an AE was ongoing at the time of first IP intake and if there was no change or an improvement in its toxicity grade or its seriousness status, this AE was not considered as treatment-emergent.
Serious TEAE was defined as a TEAE that
Resulted in death and was life-threatening;
Required in-patient hospitalization or prolongation of existing hospitalization;
Resulted in persistent or significant disability/incapacity;
Was a congenital anomaly / birth defect;
Was medically significant;
From first dose of study drug until end of the study (up to 8 weeks)
Secondary Plasma Concentration (Ctrough) of GLPG3970 Ctrough was defined as plasma concentration level at the end of the dosing interval. Day 15: pre-dose; Day 29: pre-dose; Day 43: pre-dose
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4